SCHEMBL12065641

SCHEMBL12065641

OCCOC(c1ccc(OC(F)(F)F)cc1)c1nc2cc(F)ccc2[nH]1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALPL P05186 1/20 0.38
ALPI P09923 1/20 0.38
ALPG P10696 1/20 0.38
SCN10A Q9Y5Y9 1/20 0.37
TRPA1 O75762 2/20 0.36
PPM1A P35813 1/20 0.34
GPR139 Q6DWJ6 1/20 0.34
TRPV1 Q8NER1 1/20 0.33
PDE2A O00408 3/20 0.33
ABL1 P00519 1/20 0.33
RUNX1 Q01196 1/20 0.33
MTOR P42345 1/20 0.33
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
KMT2A Q03164 1/20 0.33
TRPV4 Q9HBA0 1/20 0.32
MLKL Q8NB16 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12066063 0.93 SCN10A (0.38) ALPLALPIALPGSCN10ATRPA1
SCHEMBL12065659 0.92 SCN10A (0.39) ALPLALPIALPGSCN10ATRPA1
SCHEMBL12065633 0.89 SCN10A (0.41) SCN10ATRPA1GPR139TRPV1PDE2A
SCHEMBL12065255 0.87 SCN10A (0.40) ALPLALPIALPGSCN10ATRPA1
SCHEMBL14770728 0.87 ALPL (0.40) ALPLALPIALPGKDM4EKMT2A
SCHEMBL12065615 0.87 SCN10A (0.38) ALPLALPIALPGSCN10ATRPA1
Oxalic Acid SCHEMBL14762710 0.84 PDE2A (0.38) SCN10AGPR139PDE2AMLKL
Phosphoric Acid SCHEMBL14763404 0.84 PDE2A (0.38) SCN10AGPR139TRPV1PDE2AMTOR
SCHEMBL12066547 0.84 SCN10A (0.43) SCN10ATRPA1PDE2AMTORMLKL
SCHEMBL14762836 0.84 MLKL (0.48) ALPLALPIALPGSCN10ATRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US claimed
EP-2578573-A1 FUSED IMIDAZOLE DERIVATIVE TOA Eiyo Ltd. (JP) 2013-04-10 EP claimed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US claimed
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US disclosed
EP-2578573-A1 FUSED IMIDAZOLE DERIVATIVE TOA Eiyo Ltd. (JP) 2013-04-10 EP disclosed
WO-2011148956-A1 FUSED IMIDAZOLE DERIVATIVE トーアエイヨー株式会社 (JP) 2011-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A ALPL 4272/4885ALPI 3147/4885ALPG 3384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.